first reported that based on integrated lipid metabolomics, serum pharmacochemistry, network pharmacology, and experimental validation, the potential mechanism of Sanmiao Wan in treating RA involves reducing the activity of TNF, IL-6, and MMP-3, as well as modulating glycerophospholipid and sphingolipid metabolism, which provides important clinical insights (86). The gene discussed is TNF; the disease is rheumatoid arthritis.